Mandibular Bone Loss Predicts Subsequent Height Loss
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
TUESDAY, July 11, 2023 -- Mandibular bone loss predicts future height loss for women, according to a study published online July 4 in BMJ Open.
Nivetha Natarajan Gavriilidou, from the Karolinska Institute in Stockholm, and colleagues conducted a population-based study involving 937 Swedish women born in 1914, 1922, and 1930 to estimate whether mandibular bone structure predicts future height loss. At the baseline examination, participants were aged 38, 46, and 54 years. Height loss was calculated over three 12- to 13-year periods: 1968 to 1980; 1980 to 1992; and 1992 to 2005.
The researchers found that over the three observation periods, mean annual height loss measures were 0.075, 0.08, and 0.18 cm/year, respectively, corresponding to absolute decreases of 0.9, 1.0, and 2.4 cm, respectively. Height loss 12 years later was significantly predicted by cortical erosion in 1968, 1980, and 1992. Significant shrinkage over 12 years was also predicted by sparse trabeculation in 1968, 1980, and 1992. Consistent findings were seen, except for cortical erosion in 1968 to 1980, in multivariable regression analyses adjusting for baseline covariates, including height, birth year, physical activity, smoking, body mass index, and education.
"Mandibular bone structure alterations such as severe cortical erosion and sparse trabeculation predicted height loss," the authors write. "They may therefore serve as proxy indicators when screening in the early phases of bone degenerative pathogenesis."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
![](/img/logo/vendor/healthday-logo.png)
© 2024 HealthDay. All rights reserved.
Posted July 2023
Read this next
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
Self-Administered Gerocognitive Exam Improves Detection of Cognitive Issues in Primary Care
TUESDAY, July 2, 2024 -- A self-administered gerocognitive examination (SAGE) is easily incorporated into primary care provider (PCP) visits, and its use significantly increases...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.